Cipla wins US FDA approval for generic Advair Diskus across three strengths
XLV•US FDA clears generic Advair Diskus
Cipla received US FDA clearance for its generic Advair Diskus inhalation powder across all three strengths.
- The drug targets asthma and COPD; IQVIA pegs the US market at about $908 million.
- Cipla flagged the clearance as its first US-made dry powder inhaler approval from its US manufacturing network.
